Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis : results from a European collaborative study

Show full item record



Permalink

http://hdl.handle.net/10138/164754

Citation

Gabay , C , Riek , M , Hetland , M L , Hauge , E-M , Pavelka , K , Tomsic , M , Canhao , H , Chatzidionysiou , K , Lukina , G , Nordstrom , D C , Lie , E , Ancuta , I , Victoria Hernandez , M , van Riel , P L M C , van Vollenhoven , R & Kvien , T K 2016 , ' Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis : results from a European collaborative study ' , Annals of the Rheumatic Diseases , vol. 75 , no. 7 , pp. 1336-1342 . https://doi.org/10.1136/annrheumdis-2015-207760

Title: Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis : results from a European collaborative study
Author: Gabay, Cem; Riek, Myriam; Hetland, Merete Lund; Hauge, Ellen-Margrethe; Pavelka, Karel; Tomsic, Matija; Canhao, Helena; Chatzidionysiou, Katerina; Lukina, Galina; Nordstrom, Dan C.; Lie, Elisabeth; Ancuta, Ioan; Victoria Hernandez, M.; van Riel, Piet L. M. C.; van Vollenhoven, Ronald; Kvien, Tore K.
Contributor: University of Helsinki, Clinicum
Date: 2016-07
Language: eng
Number of pages: 7
Belongs to series: Annals of the Rheumatic Diseases
ISSN: 0003-4967
URI: http://hdl.handle.net/10138/164754
Abstract: Objectives To examine the effectiveness of tocilizumab (TCZ) with and without synthetic disease-modifying antirheumatic drugs (sDMARDs) in a large observational study. Methods Patients with rheumatoid arthritis treated with TCZ who had a baseline visit and information on concomitant sDMARDs were included. According to baseline data, patients were considered as taking TCZ as monotherapy or combination with sDMARDs. Main study outcomes were the change of Clinical Disease Activity Index (CDAI) and TCZ retention. The prescription of TCZ as monotherapy was analysed using logistic regression. CDAI change was analysed with a mixed-effects model for longitudinal data. TCZ retention was analysed with a stratified extended Cox model. Results Multiple-adjusted analysis suggests that prescription of TCZ as monotherapy varied according to age, corticosteroid use, country of the registry and year of treatment initiation. The change of disease activity assessed by CDAI as well as the likelihood to be in remission were not significantly different whether TCZ was used as monotherapy or in combination with sDMARDs in a covariate-adjusted analysis. Estimates for unadjusted median TCZ retention were 2.3 years (95% CI 1.8 to 2.7) for monotherapy and 3.7 years (lower 95% CI limit 3.1, upper limit not estimable) for combination therapies. In a covariate-adjusted analysis, TCZ retention was also reduced when used as monotherapy, with an increasing difference between mono and combination therapy over time after 1.5 years (p=0.002). Conclusions TCZ with or without concomitant sDMARDs resulted in comparable clinical response as assessed by CDAI change, but TCZ retention was shorter under monotherapy of TCZ.
Subject: CONTROLLED-STUDY SURPRISE
DOUBLE-BLIND
ADDING TOCILIZUMAB
ACT-RAY
INADEQUATE RESPONSES
MULTIPLE IMPUTATION
RECEPTOR INHIBITION
CONTROLLED-TRIAL
METHOTREXATE
MONOTHERAPY
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1336.full.pdf 527.5Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record